Sixfold Bioscience is an award-winning, Y Combinator and venture-backed, preclinical-stage biotech based in London. Founded by experienced researchers from Cambridge Univeristy and London's Francis Crick Institute, Sixfold develops next-generation in vivo delivery systems for gene-editing drugs and gene therapeutics. While product approvals and a regulatory focus have made 2018 a breakthrough time for Cell & Gene therapies, the focus now shifts to finding safe and effective delivery systems to help unlock their true clinical and commercial potential. Sixfold is dedicated to providing a solution to the drug delivery challenge thereby bringing cures for genetically-driven diseases to patients worldwide. 

London, UK

Sixfold Bioscience

Cantos Ventures is a pre-seed and seed-stage venture capital fund that invests in startups in 'pre-inflection' industries. We view every startup as a journey, and seek to join those with noble aims.

Your story awaits